Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP1CA | P62136 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MARS1 | P56192 | 2/20 | 0.51 |
| ▸ | RPA1 | P27694 | 7/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318841 | 0.85 | RPA1 (0.68) | PPP1CAALDH1A1L3MBTL1MARS1RPA1 | |
| SCHEMBL1143854 | 0.84 | RPA1 (0.67) | PPP1CAALDH1A1L3MBTL1MARS1RPA1 | |
| SCHEMBL954786 | 0.83 | KMT2A (0.50) | PPP1CAALDH1A1L3MBTL1RPA1MEN1 | |
| SCHEMBL1110855 | 0.82 | PPP1CA (0.87) | PPP1CAL3MBTL1MARS1RPA1SMN1; SMN2 | |
| SCHEMBL2319936 | 0.82 | RPA1 (0.54) | PPP1CAL3MBTL1MARS1RPA1SMN1; SMN2 | |
| SCHEMBL1765063 | 0.82 | PPP1CA (0.82) | PPP1CAL3MBTL1MARS1RPA1SMN1; SMN2 | |
| SCHEMBL1514559 | 0.81 | PPP1CA (1.00) | PPP1CAL3MBTL1MARS1RPA1SMN1; SMN2 | |
| SCHEMBL1143841 | 0.80 | RPA1 (0.57) | ALDH1A1L3MBTL1RPA1SMN1; SMN2MEN1 | |
| SCHEMBL2325622 | 0.80 | RPA1 (0.46) | PPP1CAALDH1A1L3MBTL1RPA1SMN1; SMN2 | |
| SCHEMBL955390 | 0.79 | KMT2A (0.50) | PPP1CAALDH1A1L3MBTL1RPA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128616-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-05-08 | — | — | US | disclosed |
| US-8664257-B2 | Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2014-03-04 | — | — | US | disclosed |
| US-20130046004-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-02-21 | — | — | US | disclosed |
| EP-2528902-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092187-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046004-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CTSF, CTSS, CTSE | PPP1CA 4330/4885KDM4E 3142/4885ALDH1A1 581/4885 |
| US-20140128616-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CTSF, CTSS, CTSE | PPP1CA 4330/4885KDM4E 3142/4885ALDH1A1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.